
Opinion|Videos|December 21, 2023
Update from the POLARIX Study on Pola-R-CHP in DLBCL
Medical oncologists discuss recent data from the POLARIX study investigating polatuzumab vedotin plus R-CHP in patients with diffuse large B-cell lymphoma.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Reanalysis of Glioblastoma Vaccine Trial Suggests Larger Survival Benefit
2
FDA Accepts NDA for Mezigdomide Combination in Relapsed/Refractory Multiple Myeloma
3
Dostarlimab Demonstrates Sustained Complete Responses in dMMR/MSI-H Rectal Cancer
4
What Long-Term Real-World Data on CAR T in Myeloma Could Reveal
5































